Do Additional Cores from MRI Cancer-Suspicious Lesions to Systematic 12-Core Transrectal Prostate Biopsy Give Better Cancer Detection?

Shigemura, Katsumi; Motoyama, Shin; Yamashita, Masuo

doi:10.1159/000334375

Cited by 9 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeted biopsy identified by MRI may be useful to improve the positive rate on first biopsy. This finding differs from the results of Shigemura et al who reported that only 1.04% of cancers had positive cores in MRI targeted biopsy alone ( 27 ). This difference may be caused by differences in prostate volume (mean 44.82 vs. 31.9 ml) and serum PSA level (mean 9.73 vs. 8.58 ng/ml) between the two studies.…”

Section: Discussioncontrasting

confidence: 99%

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Chen¹,

Yi²,

Jiang³

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The detection rate of prostate cancer (PCa) using traditional biopsy guided by transrectal ultrasound (TRUS) is not satisfactory. The aim of this study was to determine the utility of 3-Tesla (3-T) magnetic resonance imaging (MRI) prior to TRUS-guided prostate biopsy and to investigate which subgroup of patients had the most evident improvement in PCa detection rate. A total of 420 patients underwent 3-T MRI examination prior to the first prostate biopsy and the positions of suspicious areas were recorded respectively. TRUS-guided biopsy regimes included systematic 12-core biopsy and targeted biopsy identified by MRI. Patients were divided into subgroups according to their serum prostate-specific antigen (PSA) levels, PSA density (PSAD), prostate volume, TRUS findings and digital rectal examination (DRE) findings. The ability of MRI to improve the cancer detection rate was evaluated. The biopsy positive rate of PCa was 41.2% (173/420), and 41 of the 173 (23.7%) patients were detected only by targeted biopsy in the MRI-suspicious area. Compared with the systematic biopsy, the positive rate was significantly improved by the additional targeted biopsy (P=0.0033). The highest improvement of detection rate was observed in patients with a PSA level of 4–10 ng/ml, PSAD of 0.12–0.20 ng/ml2, prostate volume >50 ml, negative TRUS findings and negative DRE findings (P<0.05). Therefore, it is considered that 3-T MRI examination could improve the PCa detection rate on first biopsy, particularly in patients with a PSA level of 4–10 ng/ml, PSAD of 0.12–0.20 ng/ml2, prostate volume of >50 ml, negative TRUS findings and negative DRE findings.

show abstract

Section: Discussioncontrasting

confidence: 99%

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Chen¹,

Yi²,

Jiang³

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Shigemura et al [11] suggested that a 12-core SB can be considered an excellent tool for PCa detection and there may be no need for additional cores based on MRI findings. These data are in contrast to our findings, demonstrating an incremental value of 16% using mpMRI for PCa diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre Study

Junker

Schäfer²,

Heidegger³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Purpose: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. Patients and Methods: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. Results: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). Conclusions: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB.

show abstract

“…However, targeting accuracy relies heavily on challenging cross-modality image-to-image registration [6] and deformable registration methods [7, 8]. MRI-TRUS fusion is most likely superior to traditional systematic methods, but requires further validation and it remains to be tested if it is sufficiently accurate to make a clinical difference [9]. …”

Section: Introductionmentioning

confidence: 99%

MRI-Safe Robot for Endorectal Prostate Biopsy

Stoianovici

Kim

Srimathveeravalli

et al. 2014

IEEE/ASME Trans. Mechatron.

109

106

View full text Add to dashboard Cite

This paper reports the development of an MRI-Safe robot for direct (interventional) MRI-guided endorectal prostate biopsy. The robot is constructed of nonmagnetic and electrically nonconductive materials, and is electricity free, using pneumatic actuation and optical sensors. Targeting biopsy lesions of MRI abnormality presents substantial clinical potential for the management of prostate cancer. The paper describes MRI-Safe requirements, presents the kinematic architecture, design and construction of the robot, and a comprehensive set of preclinical tests for MRI compatibility and needle targeting accuracy. The robot has a compact and simple 3 degree-of-freedom (DoF) structure, two for orienting a needle-guide and one to preset the depth of needle insertion. The actual insertion is performed manually through the guide and up to the preset depth. To reduce the complexity and size of the robot next to the patient, the depth setting DoF is remote. Experimental results show that the robot is safe to use in any MRI environment (MRI-Safe). Comprehensive MRI tests show that the presence and motion of the robot in the MRI scanner cause virtually no image deterioration or signal to noise ratio (SNR) change. Robot’s accuracy in bench test, CT-guided in-vitro, MRI-guided in-vitro and animal tests are 0.37mm, 1.10mm, 2.09mm, and 2.58mm respectively. These values are acceptable for clinical use.

show abstract

Do Additional Cores from MRI Cancer-Suspicious Lesions to Systematic 12-Core Transrectal Prostate Biopsy Give Better Cancer Detection?

Cited by 9 publications

References 61 publications

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre Study

MRI-Safe Robot for Endorectal Prostate Biopsy

Contact Info

Product

Resources

About